• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » HGS’s Benlysta grosses $59 million

HGS’s Benlysta grosses $59 million

January 11, 2012
CenterWatch Staff

Benlysta (belimumab), the first approved drug for systemic lupus in 56 years, has already grossed $59.2 million, averaging $2.3 million in sales per week since it received FDA approval less than a year ago, according to Human Genome Sciences (HGS).

This treatment for adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) is quickly spreading, and has already been approved in Canada and at least eight European countries.

In December 2011, HGS and GlaxoSmithKline (GSK) announced that dosing of patients had been initiated in BLISS-SC, a phase III trial of the subcutaneous formulation of Benlysta. If this trial is successful and regulatory authorities agree, the subcutaneous formulation would make it possible for patients to self-administer Benlysta by injection once a week.

“We are pioneering a treatment in a market that has not seen a new option for patients in decades,” said H. Thomas Watkins, president and CEO of HGS. “Although we are still in the early adoption phase of our launch, our experience in the market to date reinforces our belief that Benlysta will ultimately play a major role in improving the standard of care for SLE patients.”

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing